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Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular alterations and immunological disturbances and
fibrosis, the order of which remains to be fully determined. Clinically, patients show clear signs of hypoxia in skin and internal
organs. The low oxygen tension is potentially caused by a yet to be indentified circuitry involving the three features that typify
SSc. In addition, once present, the hypoxia creates a vicious circle of ongoing pathology. In this paper, we provide an overview of
the evidence that points towards the mechanisms causing hypoxia in SSc. In addition, data that suggest how hypoxia itself may
orchestrate worsening of symptoms is presented. Altogether, it is clear that hypoxia is an important hallmark in SSc patients. By
providing an overview of the mechanisms at play and the possible therapeutic avenues that have emerged, we hope to stimulate
researchers to provide novel clues into the conundrum in SSc patients.
1. Introduction
Systemic sclerosis (SSc) is typified by vascular alterations
and immunological disturbances and fibrosis of the skin and
internal organs, which culminates in severe disabilities and
not seldom premature death. Although the abovementioned
pathways are all clearly involved, their sequel and relative
contributions are still a matter of debate. About 90% of
the patients diagnosed with SSc experienced Raynaud’s
phenomenon long before the appearance of other clinical
symptoms that drives the patient to visit a physician [1].
The diagnosis is often made when patients suﬀer from a
full-blown SSc with rarefaction of the small capillaries as
identified by capillaroscopy, digital ulcers, and progressive
fibrosis of the skin [2, 3]. Both Raynaud’s phenomenon and
the rarefaction of capillaries suggest the presence of hypoxia
during certain stages of disease. In line with these thoughts,
several studies demonstrated a lowered oxygen pressure in
SSc skin [4–6]. Data showing a lower pO2 only in the
lesional SSc skin and a correlation between skin thickness
and pO2 suggests a direct connection between fibrosis and
tissue hypoxia. Lastly, evidence of increased oxidative stress,
thought to be caused by ischemia-reperfusion events, is con-
vincing [7, 8]. The precise contribution of the clinically clear
hypoxia to the cellular derogatory mechanism is exposed bit
by bit. Next to this aberrant regulation of oxygen system,
a role for the dysregulated immune system is illustrated by
the fact that 75–90% of patients have ANA positivity, mostly
explained by the presence of anticentromere or antitopoiso-
merase antibodies (reviewed in [9]). Recent literature shows
the potential interaction between the vascular alterations and
the immunopathology found in SSc. The rarefaction of the
small vessels clearly lowers oxygen pressure in the skin, and
there are signs of increased oxidative stress, which both are
able to alarm and activate the plethora of diﬀerent cell types
of the immune system Figure 1.
1.1. HIF-1α. As a result of the hypoxia in skin and other
aﬀected tissue in SSc, activation of important hypoxia path-
ways is plausible. The identification of hypoxia-inducible
factor 1 (HIF-1) unlighted the cellular mechanism of oxygen
homeostasis. As a transcription factor of genes important in
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Figure 1: Hypoxia in the pathogenesis of systemic sclerosis. The left side illustrates the normal situation, with a healthy blood vessel
delivering oxygen to the surrounding tissue. The right side represents the situation in SSc, where the diseased vessel and overwhelming
deposition of collagen fibers prevent the oxygen from reaching the periphery. In the vessel, endothelial apoptosis as a result of antibody-
dependent cytotoxicity is visible. Surrounding the ECs, activated pericytes are responsible for the deposition of collagen. The resulting
hypoxia leads to a higher cyto- and chemokine production by DCs, in part triggered by TLR stimulation, and to a continuing loop of TGFβ
production, collagen synthesis, andmyofibroblast diﬀerentiation of fibroblasts. This in turn leads to a hindered dispersion of oxygen, keeping
the vicious circle going on.
the metabolism of the cell but also angiogenesis, apoptosis,
proliferation, and matrix production, this factor seems to
play a more then central role in the cellular response
to changing oxygen pressures (reviewed in [10]). HIF-1α
is the tightly regulated form of HIF-1, which is quickly
hydroxylated and degraded in normoxic conditions by prolyl
hydroxylases [11]. But in case of hypoxia, the levels of HIF-1α
increase dramatically [12]. Counterintuitive however, HIF-
1αwas found to be decreased in the epidermis of SSc patients
compared to healthy controls [6]. As nicely suggested in the
review by Beyer et al. [13], this could be caused by a negative
feedback loop causing an increase in prolyl hydroxylases
resulting in a faster degradation of HIF-1α. The persistent
upregulation of VEGF (further discussed below) in SSc illus-
trates the activation of pathways sensitive to oxygen pressure
and thus the low expression of HIF-1αmust be compensated
by other factors like HIF-2α and HIF-3α. The presence of
these factors in SSc is currently unknown, and, moreover,
the function of these factors is not mutually exclusive with
HIF-1α [14]. Furthermore, a French cohort SSc patients
showed an increased presence of a genetic variant of HIF-
1α, implying a role in SSc pathogenesis [15]. How a defective
HIF-1α regulation is precisely involved in the development
of SSc will be discussed in detail later in this paper.
2. Vasculopathy
Of the three pathogenic features in SSc, vasculopathy is
thought to be the first one to occur [16]. The vascular
defects can be made visible with nailfold capillaroscopy,
showing giant capillaries, loss of architectural arrangement,
hyperpermeability, and dropout of capillaries [2]. The lower
density and quality of vessels leads to a reduced blood flow
and consequential tissue hypoxia.
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The absence or aberrant function of dermal endothelial
cells (ECs) is one mechanism often addressed to explain
the onset of vasculopathy. ECs can be distinguished on
immunohistochemistry by the expression of CD31, von
Willebrand factor (vWF), and vascular endothelial cadherin
(VE-cadherin). Dermis of early diﬀuse SSc patients (disease
duration <2 years in 27/30 patients) shows a population
of CD31+ endothelial cells with no expression of vWF and
VE-cadherin [17]. Another group observed apoptotic vWF
positive cells in skin section from early diﬀuse SSc patients,
indicating apoptosis of EC. In the UCD 200/206 chicken
SSc model, this apoptosis of ECs was already present before
the appearance of perivascular infiltrates or fibrosis [16] and
was also identified in the lungs, esophagus, and kidneys
[18]. The presence of immunoglobulins (Ig) on these ECs
[16] points towards a role of antiendothelial cell antibodies
(AECA), which are known to be present in the serum of
SSc patients [19]. The induction of EC apoptosis is thought
to be the result of antibody-dependent cellular cytotoxicity
[20, 21], and Sgonc et al. have suggested that natural killer
(NK) cells form a likely candidate to initiate this process
[22].
Next to the increased loss of ECs due to apoptosis, there
might also be a problem in endothelial repair in SSc. SSc
patients show a decreased amount of bone-marrow (BM)
resident endothelial progenitors, while the hematopoiesis
of other cell lines seems to be undisturbed [23]. The
decreased amount of BM resident endothelial precursors
could be a consequence of the above-mentioned AECA,
which can induce apoptosis of the precursors upon exposure
to AECA-positive serum [23]. Another mechanism to be
considered is a higher eﬄux of these progenitor cells to
the periphery, possibly as a result of elevated VEGF levels
(as discussed in the next paragraph) [24]. Of interest in
this light are the articles showing an increased amount
of circulating endothelial progenitors cells (CEP) [25, 26],
although there are also groups reporting a conflicting lower
number of CEP [27]. These latter are more in line with
a hampered recruitment of the BM progenitor cells to the
periphery. There was no diﬀerence between patient and
healthy control CEP when looking at VE-cadherin, CD31,
and vascular endothelial growth factor receptor 2 (VEGFR-
2) [27, 27]. Nevertheless, the capacity to diﬀerentiate in
vitro to EC is diminished in SSc progenitors, as shown
by a tempered induction of vWF after prolonged culture
[27]. On the other hand, healthy control (HC) and SSc
CEP show an equal ability to form tubules when cultured
on a Matrigel matrix in vitro [28]. Thus, in principal,
SSc CEP should be able to form coherent and functional
vessels.
In normal circumstances, hypoxia induces the expression
of angiogenic factors to stimulate angiogenesis. One of the
key angiogenic growth factors is vascular endothelial growth
factor (VEGF), which is produced by, among others, fibrob-
lasts in response to HIF-1α [6]. Despite the low presence of
HIF-1α in SSc, the expression of VEGF is increased in serum
and skin of SSc patients [6, 29]. The ongoing induction
of VEGF must then be caused by another mechanism, like
the eﬀect of the inflammatory cytokines interleukin 1 (IL-1)
and platelet-derived growth factor (PDGF). These are highly
present in SSc [30, 31] and can indeed induce the expression
of VEGF in fibroblasts [6].
The eﬀects of VEGF are regulated by its receptors, VEGF
receptor 1 and 2 (VEGFR-1 and VEGFR-2). From these,
VEGFR-2 is the eﬀecting molecule and VEGFR-1s main
function is to regulate the phosphorylation and activation of
the other [32]. In scleroderma skin, both receptors are found
to be higher present with an intenser staining for VEGFR-2
than for VEGFR-1 [6]. Exposure of EC to hypoxia in vitro
showed a downregulation of VEGFR-2 and upregulation of
VEGFR-1 in HC and SSc samples; the latter showed a lower
expression in SSc EC [28]. This diﬀerential regulation can
make the cells more responsive for VEGF. Correct timing
of VEGF upregulation results in recruitment of EPC and
formation of new vessels, which improves the oxygen supply
to the tissue. In contrast, an ongoing VEGF stimulus caused
by a higher VEGF and a defective regulation due to a relative
decrease in VEGFR-1 elicits the formation of aberrant vessels
[33], resembling the anomalous vessels seen on nailfold
capillaroscopy in SSc [2].
In conclusion, in SSc, the vascular reaction to hypoxia
is dominated by the growth factor VEGF. On the other
hand, there is the altered quantity and phenotype of the
ECs and their progenitors, which could be a causal factor in
the appearance of hypoxia in SSc. The fact that this altered
phenotype is not present in the EC of patients who were
treated with intensive immunotherapy and subsequent stem
cell transplantation is a promising thought [17]. This could
imply reversibility of the vascular defects and might open
novel avenues for therapeutic intervention.
3. The Dysfunctional Immune System
It is by now generally accepted that hypoxia can induce
inflammation and that inflammation itself causes hypoxia in
tissues. The decrease in oxygen tension during inflammation
is a logic result of the increasing metabolic demand of
cells, thrombosis, and compression of the vessels due to
edema (interstitial hypertension). The eﬀect of hypoxia,
causing a proinflammatory environment throughout the
body, is nicely illustrated by individuals that spend time
at extreme height and display increased levels of IL-6 and
CRP [34]. Furthermore, we know from transplantation
medicine that the expression of Toll-like receptors (TLRs)
and pro-inflammatory cytokines correlates with the amount
of ischemia [35, 35, 36].
The main TLR-expressing cells are the cells of the innate
immune system, especially the antigen-presenting cells. In
response to the hypoxic environment during inflammation,
these cells need to increase their expression of HIF-1α for
a proper function. This was elegantly demonstrated in
phagocytes from HIF knockout mice that could not eﬃ-
ciently remove bacteria and get persistent ulcers [37, 38].
Diﬀerentiation and maturation of dendritic cells (DCs) is
inhibited under hypoxic conditions [39] but they showed
an increased production of CXCL1, VEGF, CXCL8, and
CXCL10 [40, 41], all of which increased in SSc [29, 42, 43].
In contrast with these latter observations, these hypoxic
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DCs showed a lowered CCL2 and CCL18 production [40,
41], two pivotal chemokines that are repeatedly found
to be increased in the circulation of SSc patients [43,
44]. Interestingly, other research showed an increased DC
maturation and costimulatory capacity after TLR ligation
during hypoxia [45, 46], suggesting that these cells are
already in an activated state. Taking into account the
endogenous TLR4 ligands found in SSc serum [47], the
increased cytokine production in response to TLR ligands
[48], and the increase in circulating cytokines mainly
produced by these antigen presenting cells, it is tempting to
speculate about a role for the hypoxic environment in this
condition and this justifies further research to unravel this
conundrum.
The eﬀects of lowered oxygen pressure on the adaptive
immune system are also quite evident. Hypoxia increases
the expression of IL-10, TGF-b, galectin-1, and Foxp3, all
supporting the development of regulatory T cells (Tregs)
in hypoxic conditions. This is in line with several studies
that reported increased numbers of Tregs in the circu-
lation of SSc patients [49–51]. HIF-1α expression in T
lymphocytes enhances the apoptotic rate and decreases T-
cell function. In line with this, conditional deletion of HIF-
1α in T and B cells is associated with the appearance of
autoimmune responses in mice [52]. More intriguingly,
the HIF-1α deficient T lymphocytes produced more pro-
inflammatory cytokines in response to TCR triggering than
HIF-1α expressing control cells [53, 54]. Taken into account
the low HIF-1α expression in SSc patients, even in low
oxygen conditions, it is tempting to suggest that the function
of T lymphocytes in SSc is diverted by their impaired
response to the hypoxic condition. Altogether, a hypoxic
environment as present in SSc patients has clear eﬀects
on the immune system which might be augmented by an
inherent defect to adept to low oxygen concentrations by SSc
cells. Research focused on the eﬀect of hypoxia on immune
cells from SSc patients however is scarce and needs more
attention in future investigations. Next to that, the underly-
ing circuitry that explains this possible altered response to
hypoxia by SSc cells remains elusive and warrants further
investigation.
4. Fibrosis
Fibrosis is regarded to be the end stage of SSc and is often
thought to cause the majority of the clinical symptoms. It
is no wonder that most of the research of the last decades
in this field focused on fibroblast biology and hypoxia as a
causative factor for the extensive extracellular matrix (ECM)
deposition.
A lower supply of oxygen to the tissue can be caused by
vessel depletion or impaired diﬀusion. Where vasculopathy
can be the cause of the former, fibrosis can lead to the latter.
An important eﬀector cell in this perivascular fibrosis is the
pericyte. Pericytes can be found together with ECs around
capillaries and show characteristics resembling vascular
smoothmuscle cells (SMCs) [55, 56]. In the perivascular area
in SSc skin, pericytes with a myofibroblast phenotype have
been observed, expressing alpha smooth muscle actin (α-
SMA) and ED-A splice variant fibronectin (ED-A FN). These
cells also show expression of the cell-surface glycoprotein
Thy1 [57], which is essential in the diﬀerentiation of fibro-
blasts to myofibroblasts [58]. The upregulation of α-SMA in
pericytes is associated with collagen production [59]. Fur-
thermore, a reduced endothelial growth was observed when
combining pericytes and EC in culture [56]. Taking together,
these myofibroblast-like cells can lead to both perivascular
fibrosis and endothelial dysfunction and thus cause a reduced
supply of oxygen to the tissue.
The excessive production of ECM components by fibrob-
lasts in reaction to transforming growth factor beta (TGFβ)
and connective tissue growth factor (CTGF) is a paradigm
in scleroderma [60]. Lately, there seems to be a paradigm
shift noting that this excessive ECM production is not only
due to an intrinsic defect in the fibroblasts, but also in
part caused by a normal reaction of these fibroblasts to the
pathological environment present in SSc patients. Indeed, in
hypoxic circumstances, fibroblasts from SSc patients and HC
react in the same profibrotic way. Exposure of fibroblasts to a
low oxygen environment leads toHIF-1α-dependent upregu-
lation of both TGFβ and CTGF [61–63]. Stabilization of HIF-
1α, as occurs during hypoxia, also elevates the sensitivity of
cells towards TGFβ, leading to a quicker TGFβ-dependent
upregulation of CTGF. Herein could lay the explanation
for the heightened serum CTGF in SSc [62]. Moreover,
during hypoxia, the fibroblasts show an upregulation of
genes involved in ECM synthesis and regulation, including
fibronectin, thrombospondin, proα2(I) collagen (COL1A),
and lysyl hydroxylase 2 (LH2) [64, 65]. This upregulation
is in part regulated by HIF-1α, but totally dependent on
TGFβ [64]. Last but not least, the hypoxic damage and
oxidative stress could induce tissue damage and the sub-
sequent release of associated molecular patterns (DAMPs),
which could in turn stimulate TLRs on the fibroblasts and
thus lead to activation [66].
Epithelial-to-mesenchymal transition (EMT) is a novel
concept in fibrosis of lung and kidney, two severe complica-
tions of SSc. It describes a process in which epithelial cells
develop mesenchymal characteristics, such as an increased
expression of α-SMA and vimentin and a decrease in
expression of E-cadherin. TGFβ is the prototypic stimulus
of EMT [67]. EMT can also be induced by a lower oxygen
pressure, as is shown by hypoxic culture of alveolar and
kidney tubulus epithelial cells. The role of HIF-1α and TGFβ
in this transition seems to be dependent on the origin of the
epithelial cells. In alveolar cells, both molecules are required
for EMT, while in kidney epithelium the process seems
to be independent of these two proteins [4, 61]. Recently,
EMT has been observed in the skin of a murine SSc model,
suggesting that this process may be involved in both dermal
and pulmonal fibrosis [68].
In contrast to the long-thought intrinsic defect in
fibroblasts, data show that these cells respond in a normal
way to abnormal circumstances. Taking the abovementioned
together, there is evidence that in SSc hypoxia can lead to
diﬀerentiation and activation of fibroblasts but might have
similar eﬀects on primary immune cells all contributing to
an extensive ECM deposition.
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5. Conclusion
Most human cells are able to adapt to a broad range of oxygen
tension varying between 40–100mmHg in the circulation
and 4–20mmHg in tissue. In contrast to these physiological
diﬀerences, in certain condition pathological hypoxia devel-
ops. In SSc patients pathological hypoxia is obvious only by
looking at their hands and seeing the digital ulcers patients
suﬀer from. The response to this loss of oxygen has to be well
coordinated and tightly regulated by factors like HIF-1α. The
hypoxia caused by a combination of activated immune cells
(increasingmetabolic demands), rarefaction of blood vessels,
and perivascular fibrosis becomes detrimental without this
regulation. In SSc, there is no sign of increasing HIF-1α
activity and therefore the low oxygen tension can go on acti-
vating fibroblasts (etc.), aggravating immune responses, and
impairing endothelial cells and thereby further increasing
the hypoxic environment. Moreover, the ongoing hypoxia
will increase TGFβ levels and will therefore increase the
production of extracellular matrix, further increasing fibrosis
and thus the distance to the closest blood vessel [64, 69, 69].
Interestingly, another detrimental eﬀect of hypoxia is shown
in cancer research by the profibrotic and proinflammatory
eﬀect of the increased reactive oxygen species and autophagy
caused by low oxygen tension [70]. Eventually, it seems
inescapable that the system will choke in its own vicious
circle. As shown by the eﬀect of stem cell therapy [17], there
are options to interfere in this ongoing process. For example,
one would be able to interfere in the impaired response to
hypoxia more specifically by the use of propyl-hydroxylase
inhibitors (reviewed in [71]). In addition, the pharmaco-
logical increase of bilirubin by the use of atazanavir could
directly provide more anti-inflammatory agents thereby
bypassing the dysfunctional hypoxic pathway [72]. These
therapeutic interventions could be given systemically but,
alternatively, could also be specifically targeted to certain
cells of the immune cells by exploiting recent knowledge on
liposomes or even nanoparticles. In conclusion, the research
field on therapeutic interventions in detrimental hypoxia is
growing which will hopefully lead to the broadening of our
therapeutic armamentarium to treat this disease.
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